Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity

Endocrinology

Volumn 151, Issue 10, 2010, Pages 4820-4829

  Gu, Yusu ^a   Zhang, Kuixing ^a   Biswas, Nilima ^a,b   Friese, Ryan S ^a   Lin, Dennis H ^a   Mahata, Sushil K ^a,b   Hoshijima, Masahiko ^a   O'Connor, Daniel T ^a,b   Peterson, Kirk L ^a   Brar, Bhawanjit K ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; PARATHYROID HORMONE; THYROID HORMONE; TYROSINE 3 MONOOXYGENASE; UROCORTIN II; CHROMOGRANIN A; CHROMOGRANIN A, MOUSE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; UROCORTIN;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; CHROMAFFIN CELL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE; TELEMETRY; ADRENAL GLAND; ADRENERGIC NERVE; ANIMAL; AUTONOMIC NEUROPATHY; BLOOD; BLOOD PRESSURE; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEART RATE; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENAL GLANDS; ADRENERGIC FIBERS; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CATECHOLAMINES; CHROMOGRANIN A; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HEART RATE; HYPERTENSION; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TYROSINE 3-MONOOXYGENASE; UROCORTINS;

EID: 77957266561     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1454     Document Type: Article

References (48)

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale WW 1995 Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292
2. Hsu SY, Hsueh AJ 2001 Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605-611
3. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE 2001 Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848 (Pubitemid 32209571)
4. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW 2001 Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575
5. Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ 2008 Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105:3939-3944
6. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee KF 2002 Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99:7734-7739
7. Perrin MH, Vale WW 1999 Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 885:312-328
8. Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M, Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN 2007 Corticotropin- releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology 148:1524-1538
9. Rademaker MT, Charles CJ, Nicholls MG, Richards AM 2008 Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci (Lond) 114:635-642 (Pubitemid 351589062)
10. Grossini E, Molinari C, Mary DA, Marino P, Vacca G 2008 The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol 578:242-248 (Pubitemid 350309583)
11. Gardiner SM, March JE, Kemp PA, Bennett T 2007 A comparison between the cardiovascular actions of urocortin 1 and urocortin 2 (stresscopin-related peptide) in conscious rats. J Pharmacol Exp Ther 321:221-226 (Pubitemid 46456961)
12. Rademaker MT, Cameron VA, Charles CJ, Richards AM 2005 Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112:3624-3632
13. Wiley KE, Davenport AP 2004 CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143:508-514
14. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL 2004 The cardiovascular physiological actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101:3697-3702 (Pubitemid 38338257)
15. Chen CY, Doong ML, Rivier JE, Taché Y 2003 Intravenous urocortin II decreases BP through CRF(2) receptor in rats. Regul Pept 113:125-130
16. Dieterle T, Meili-Butz S, Bühler K, Morandi C, John D, Buser PT, Rivier J, Vale WW, Peterson KL, Brink M 2009 Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? Hypertension 53:739-744
17. Kim T, Tao-Cheng JH, Eiden LE, Loh YP 2001 Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 106:499-509
18. O'Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK,Wu H, Kennedy BP, Ziegler MG, Wright FA, Schlager G, Parmer RJ 1999 Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 8:285-295 (Pubitemid 30220292)
19. O'Connor DT, Zhu G, Rao F, Taupenot L, Fung MM, Das M, Mahata SK, Mahata M, Wang L, Zhang K, Greenwood TA, Shih PA, Cockburn MG, Ziegler MG, Stridsberg M, Martin NG, Whitfield JB 2008 Heritability and genome-wide linkage in U.S. and Australian twins identify novel genomic regions controlling chromogranin A: implications for secretion and blood pressure. Circulation 118:247-257
20. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK 2005 Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942-1952 (Pubitemid 40979734)
21. Binder A 2007 A review of the genetics of essential hypertension. Curr Opin Cardiol 22:176-184
22. Grassi G 2004 Sympathetic and baroreflex function in hypertension: implications for current and new drugs. Curr Pharm Des 10:3579-3589 (Pubitemid 39386574)
23. Bobrovskaya L, Gilligan C, Bolster EK, Flaherty JJ, Dickson PW, Dunkley PR 2007 Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis. J Neurochem 100:479-489 (Pubitemid 46011008)
24. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, DiGruccio M, Vaughan J, Reubi JC, Waser B, Koerber SC, Martinez V, Wang L, Taché Y, Vale W 2002 Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45:4737-4747
25. Lucot JB, Jackson N, Bernatova I, Morris M 2005 Measurement of plasma catecholamines in small samples from mice. J Pharmacol Toxicol Methods 52:274-277 (Pubitemid 41207204)
26. Shibuya I, Utsunomiya K, Toyohira Y, Ueno S, Tsutsui M, Cheah TB, Ueta Y, Izumi F, Yanagihara N 2002 Regulation of catecholamine synthesis by leptin. Ann NY Acad Sci 971:522-527
27. Friese RS, Gayen JR, Mahapatra NR, Schmid-Schönbein GW, O'Connor DT, Mahata SK 2010 Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiol Genomics 40:195-207
28. Gardiner SM, March JE, Kemp PA, Davenport AP, Wiley KE, Bennett T 2005 Regional hemodynamic actions of selective corticotropin- releasing factor type 2 receptor ligands in conscious rats. J Pharmacol Exp Ther 312:53-60 (Pubitemid 40096452)
29. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards M 2007 Urocortin 2 infusion in human heart failure. Eur Heart J 28:2589-2597
30. Montesinos MS, Machado JD, Camacho M, Diaz J, Morales YG, Alvarez de la Rosa D, Carmona E, Castañeyra A, Viveros OH, O'Connor DT, Mahata SK, Borges R 2008 The crucial role of chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. J Neurosci 28:3350-3358
31. Døskeland AP, Flatmark T 2002 Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. Eur J Biochem 269:1561-1569
32. Wong DL, Tank AW 2007 Stress-induced catecholaminergic function: transcriptional and post-transcriptional control. Stress 10:121-130
33. Udelsman R, Blake MJ, Holbrook NJ 1991 Molecular response to surgical stress: specific and simultaneous heat shock protein induction the adrenal cortex, aorta, and vena cava. Surgery 110:1125-1131
34. Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, Czyzyk- Krzeska MF 2003 Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia- inducible transcription factors. J Neurochem 85:483-491
35. Nakashima A, Hayashi N, Kaneko YS, Mori K, Sabban EL, Nagatsu T, Ota A 2007 RNAi of 14-3-3eta protein increases intracellular stability of tyrosine hydroxylase. Biochem Biophys Res Commun 363:817-821
36. Li SG, Lawler JE, Randall DC, Brown DR 1997 Sympathetic nervous activity and arterial pressure responses during rest and acute behavioral stress in SHR versus WKY rats. J Auton Nerv Syst 62:147-154
37. Esler M, Kaye D 1998 Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 72:210-219
38. Kumai T, Tateishi T, Tanaka M, Watanabe M, Shimizu H, Kobayashi S 2001 Tyrosine hydroxylase antisense gene therapy causes hypotensive effects in the spontaneously hypertensive rats. J Hypertens 19:1769-1773
39. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T 2001 Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 169:177-183
40. Smani T, Domínguez-Rodríguez A, Hmadcha A, Calderón-Sánchez E, Horrillo-Ledesma A, Ordóñez A 2007 Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortininduced vasodilatation of rat coronary artery. Circ Res 101:1194-1203
41. Lubomirov LT, Schubert R, Gagov HS, Duridanova DB, Pfitzer G 2006 Urocortin decreases phosphorylation ofMYPT1and increases the myosin phosphatase activity via elevation of the intracellular level of cAMP. Biofizika 51:773-780
42. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T 2003 Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 42:561-565
43. Huang Y, Chan FL, Lau CW, Tsang SY, Chen ZY, He GW, Yao X 2003 Roles of cyclic AMP and Ca2+-activated K+ channels in endothelium- independent relaxation by urocortin in the rat coronary artery. Cardiovasc Res 57:824-833
44. Lubomirov L, Gagov H, Petkova-Kirova P, Duridanova D, Kalentchuk VU, Schubert R 2001 Urocortin relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile apparatus for calcium. Br J Pharmacol 134:1564-1570
45. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW 2005 Urocortininduced relaxation in the human internal mammary artery. Cardiovasc Res 65:913-920
46. Yao X, He GW, Chan FL, Lau CW, Tsang SY, Chen ZY, Huang Y 2002 Endothelium-dependent and -independent coronary relaxation induced by urocortin. J Card Surg 17:347-349
47. Chen A, Blount A, Vaughan J, Brar B, Vale W 2004 Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology 145:2445-2457
48. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjøs OD, Latchman DS, Lee KF, Vale W 2004 Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145:24-35; discussion 21-23